During its earnings call this week, the liquid biopsy firm said it is planning a 10,000-patient trial to test its Lunar assay for colorectal cancer screening.
Take2 was founded by Chinese University of Hong Kong researchers and will commercialize a cell-free DNA test for early cancer detection.
The company presented new data on the performance of a multi-pronged liquid biopsy assay in detecting colorectal cancers across a range of clinical stages.
Following promising data from its Circulating Cell-free Genome Atlas study, the firm decided to pivot its breast cancer trial to support its multi-cancer test.
Investigators, led by Hong Kong researcher and Grail collaborator Dennis Lo, described a cancer detection strategy using cleavage patterns in circulating DNA molecules.
Though there are few direct hints at how the company plans to translate its findings to a clinical test, its early data has captured the attention of the cancer community.
The financing round will support Grail's ongoing development and validation of early cancer detection products.
23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.
China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.
In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.
NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.